Zhu Lihuan, Zhou Dongsheng, Chen Yiyong, Guo Tianxing, Chen Wenshu, Pan Xiaojie
Department of Thoracic Surgery, Fujian Provincial Hospital and Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Department of Radiology, Fujian Provincial Hospital and Provincial Clinical College, Fujian Medical University, Fuzhou, China.
Clin Med Insights Oncol. 2023 Oct 9;17:11795549231184918. doi: 10.1177/11795549231184918. eCollection 2023.
Non-small cell lung cancer (NSCLC) with mutations has a worse prognosis. It was generally more resistant to chemotherapy and radiation. Our aim was to investigate the correlation between the co-mutated gene and clinical features, and prognostic value in patients with NSCLC.
Seventy-three patients with a diagnosis of NSCLC at our hospital were recruited. They were divided into the mutation status (minor) ( MU) and wild-type (major) ( WT) groups according to their clinical characteristics after their mutation data and clinical information were collected. Serum markers were compared between groups using Mann-Whitney test. Other clinical factors were compared between groups using χ2 test and Fisher exact test. The log-rank test was used to compare survival curves.
Of the 73 patients with NSCLC, 37 (50.68%) were found to carry mutation. MU and WT groups (n = 36) showed a significant difference in the number of smokers, incidence of squamous cell carcinoma, mutation, and number of advanced patients (P < .05), while gender, age, lymph node metastasis, and mutation did not differ significantly between the 2 groups. The survival curves in the TP53/KRAS and the co-mutation groups suggest that patients with NSCLC may have a shorter progression-free survival (PFS) if they carry one of the 2 types of co-mutation.
gene mutations are more common in patients with NSCLC and squamous cell carcinoma. New predictive markers for NSCLC prognosis may be and co-mutations.
具有 突变的非小细胞肺癌（NSCLC）预后较差。它通常对化疗和放疗更具抗性。我们的目的是研究 共突变基因与临床特征之间的相关性，以及其在NSCLC患者中的预后价值。
招募了我院 73 例诊断为 NSCLC 的患者。在收集他们的突变数据和临床信息后，根据其临床特征将他们分为 突变状态（次要）（MU）组和 野生型（主要）（WT）组。使用 Mann-Whitney 检验比较组间血清标志物。使用 χ2 检验和 Fisher 精确检验比较组间其他临床因素。使用对数秩检验比较生存曲线。
在 73 例 NSCLC 患者中，发现 37 例（50.68%）携带 突变。MU 组和 WT 组（n = 36）在吸烟者数量、鳞状细胞癌发病率、 突变和晚期患者数量方面存在显著差异（P <.05），而两组之间的性别、年龄、淋巴结转移和 突变无显著差异。TP53/KRAS 组和 共突变组的生存曲线表明，携带这两种共突变类型之一的 NSCLC 患者无进展生存期（PFS）可能较短。
基因突变在 NSCLC 患者和鳞状细胞癌患者中更为常见。NSCLC 预后新预测标志物可能是 和 共突变。
